Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jerini’s Icatibant Falters in U.S., Wins In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA rejects orphan drug for hereditary angioedema, paving way for rivals to gain an edge.

You may also be interested in...



Firazyr Efficacy Findings Were Muddied By Choice Of Comparator

A pivotal trial comparing Firazyr to an active comparator not approved by FDA helped bring about the first cycle “not approvable” decision. FDA’s cross-study comparison failed to show that tranexamic acid was no worse than placebo, so the trial could have made icatibant look better than it was. A third, placebo-controlled trial ultimately sealed the deal for approval.

Shire Gets Advisory Committee Support For Firazyr Self-Administration Claim

Shire will enter discussions with FDA on labeling for its hereditary angioedema drug Firazyr (icatibant) with backing from an advisory panel for a claim to allow patients to self-administer the product, which is delivered through subcutaneous injection.

Shire Gets Advisory Committee Support For Firazyr Self-Administration Claim

Shire will enter discussions with FDA on labeling for its hereditary angioedema drug Firazyr (icatibant) with backing from an advisory panel for a claim to allow patients to self-administer the product, which is delivered through subcutaneous injection.

Related Content

Topics

UsernamePublicRestriction

Register

PS067653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel